Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission (FTC) has teed up a further extension on the deal’s review period. Catalent and the Novo Nordisk Foundation received requests for additional documents and information on the proposed deal from the FTC as part of what’s known as a “second request,” Catalent said in a securities filing. The Novo Nordisk Foundation acts as parent to both Novo Holdings and drugmaker Novo Nordisk.
Read the full article: Another Day, Another Delay for Novo’s Catalent Acquisition as FTC Imposes ‘Second Request’ //
Source: https://www.fiercepharma.com/pharma/another-day-another-30-day-waiting-period-novo-holdings-catalent-acquisition-ftc-imposes